Calyxo Raises $40M for Kidney Stone Removal Device

Calyxo, a company aiming to redefine kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors, with continued support from Questa Capital, Avidity Partners, and CRG.

The company said the financing follows the key milestone of 40,000 patients treated with its CVAC system. Calyxo also said adoption of its all-in-one aspiration-based stone removal system reflects growing clinician recognition that more complete stone clearance leads to improved outcomes.

The financing’s proceeds will be used to expand the company’s commercial infrastructure, advance clinical and health economic evidence generation through ongoing and future studies, and support kidney stone care innovation.

The CVAC System enables continuous aspiration of stone fragments, supporting more complete stone clearance. The company said that clinical, preclinical, and health economic data have consistently demonstrated low residual stone volume (RSV), improved procedural efficiency, and reductions in downstream healthcare utilization and cost.

“Ally Bridge Group is pleased to lead this financing to support Calyxo’s continued growth,” said Kevin Reilly, Managing Director, head of Medtech at Ally Bridge Group. “The company is addressing a meaningful need in kidney stone treatment with a differentiated approach supported by strong clinical validation and physician adoption. We are excited to partner with the Calyxo team as they continue to build on this momentum.”

“This financing marks an important inflection point for Calyxo,” added Joe Catanese, Ph.D., CEO of Calyxo. “More than 40,000 patients have now been treated with the CVAC System. Real-world experience, together with an established body of clinical evidence, indicates that the CVAC System is moving beyond early adoption and becoming an important part of the standard of care in kidney stone treatment. This financing allows us to move faster in advancing our technology and expanding the evidence base to further improve patient care.”